T-CELL MALIGNANCIES
Clinical trials for T-CELL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new T-CELL MALIGNANCIES trials appear
Sign up with your email to follow new studies for T-CELL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CD7 CAR T-cells) for people with T-cell cancers that have come back or not responded to standard therapy. The cells are made from the patient's own blood or from a donor. The goal is to see if this treatmen…
Matched conditions: T-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD5 CAR-T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells (or cells from a donor) that are specially trained to find and attack cancer ce…
Matched conditions: T-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 08:25 UTC
-
New nanobody CAR t therapy targets tough T-Cell cancers in early trial
Disease control Recruiting nowThis study tests a new treatment called nanobody CD5-CAR T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer ce…
Matched conditions: T-CELL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for rare blood cancers: experimental drug enters human trials
Disease control Recruiting nowThis early-stage study tests an investigational drug called ELA026 in adults with T/NK cell cancers that have come back or not responded to prior treatments. The main goals are to check safety and find the right dose. About 84 participants will be enrolled across multiple centers…
Matched conditions: T-CELL MALIGNANCIES
Phase: PHASE1 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC